Skip to main content

Innate and Adaptive Cellular Cytotoxicity Laboratory

Photo of Guido Ferrari, MD

Guido Ferrari, MD

Office: 115 Surg Oncol Res Fac, Durham, NC 27710
Campus Mail: Box 2926 Med Ctr, Durham, NC 27710
Phone: 919-684-2862
Fax: 
919-684-4288

Scientific Focus

The overall goal of the laboratory is to understand the ontogeny of HIV-1 specific MHC class I-restricted and non-restricted immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates. The studies gravitate around class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in effector cellular subsets, and development of Ab-based molecules that can engage cytotoxic effector subsets.

  • Pre-clinical evaluation of Dual-Affinity Re-Targeting molecules to eradicate HIV-1 latently infected cells.
  • Understanding differences between human and non-human primate effector functions of Fc-gamma Receptor-bearing cells.
  • Immune monitoring of Fc-mediated Ab cytotoxic responses in pre- and clinical passive and active immunization studies.

Selected Achievements

The laboratory team has worked since 2001 on testing samples from vaccine recipients for cytotoxic T lymphocyte (CTL) and antibody-dependent cellular cytotoxic (ADCC) responses as part of the AIDS Vaccine Evaluating Group (AVEG) and, subsequently, for the HIV vaccine trial network (HVTN). The laboratory team was the first to characterize vaccine-induced cross-clade clade CD8 CTL responses and the difference in class I-restricted epitope recognition between HIV-1 infected individuals and vaccine recipients. The laboratory team followed up this initial epitope mapping of cellular responses with the epitope mapping of ADCC responses.

In 2011, the team reported the anti-C1 epitope as the most recognized epitope by ADCC ab responses in infected individuals. The laboratory has gained a unique expertise in exploring the breadth and mapping of HIV-1 epitopes recognized by the cellular and humoral responses of the immune system. Its expertise has provided essential in designing the novel class of therapeutics named DARTs in collaboration with our colleagues at UNC-Chapel Hill and MacroGenics.

Contact Us

For pre- and clinical trial studies: Dr. Guido Ferrari gflmp@dm.duke.edu or Mrs. Sherry Stanfield-Oakely: sherry.oakley@dm.duke.edu

For basic science studies: Dr. Justin Pollara: justin.pollara@dm.duke.edu

For flow cytometry questions: Mrs. Joy A Pickeral, joy.pickeral@dm.duke.edu

For ELISPOT questions: Mr. Mark Berrong, mark.berrong@dm.duke.edu

For administrative questions: Mrs. Mary Oris , mary.oris@dm.duke.edu or Mrs. Melissa Kerkau, Melissa.kerkau@dm.duke.edu

Weight: 
0

Latest Publications

Wise, Megan C., Ziyang Xu, Edgar Tello-Ruiz, Charles Beck, Aspen Trautz, Ami Patel, Sarah Tc Elliott, et al. “In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity..” J Clin Invest, November 7, 2019. https://doi.org/10.1172/JCI132779.

Full Text

Pantaleo, Giuseppe, Holly Janes, Shelly Karuna, Shannon Grant, G Laissa Ouedraogo, Mary Allen, Georgia D. Tomaras, et al. “Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial..” Lancet Hiv 6, no. 11 (November 2019): e737–49. https://doi.org/10.1016/S2352-3018(19)30262-0.

Full Text

Li, Shuying S., Peter B. Gilbert, Lindsay N. Carpp, Chul-Woo Pyo, Holly Janes, Youyi Fong, Xiaoying Shen, et al. “Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial..” J Virol 93, no. 21 (November 1, 2019). https://doi.org/10.1128/JVI.02041-18.

Full Text

Rouphael, Nadine G., Cecilia Morgan, Shuying S. Li, Ryan Jensen, Brittany Sanchez, Shelly Karuna, Edith Swann, et al. “DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial..” J Clin Invest 129, no. 11 (November 1, 2019): 4769–85. https://doi.org/10.1172/JCI128699.

Full Text